Optimum Strategic Communications’ Post

Lykos Therapeutics Launches With $100 Million For MDMA Treatments The Multidisciplinary Association for Psychedelic Studies (MAPS) has officially launched Lykos Therapeutics (formerly MAPS PBC) as a for profit biotechnology company to advance MDMA assisted therapies. For decades, MAPS has been leading the psychedelic renaissance through their scientific research and advocacy efforts. The pivotal launch of Lykos marks a potential turning point in the future of commercializing MDMA assisted therapies. What's happening, why it matters, and more: https://lnkd.in/e-xZiDMM Featured | cc: Rick Doblin, Michael Mullette, William Stewart, Brom Rector, CFA, Henry Elkus, Colin Whelan, Matt Saunders, Kevin Yorn #psychedelics #biotech

🔥 The BioHub's First Ever Exclusive! 🔥 Big news from Freeline Therapeutics! They've rebranded as Spur Therapeutics and just acquired SwanBio Therapeutics! 🌟 What a huge week! Next week, we've got no other than the CEO of Spur, Michael Parini, joining us to discuss these game-changing developments! This is an episode you absolutely cannot miss. Stay tuned! 🎧 #BioHubPodcast #Exclusive #GeneTherapy #SpurTherapeutics #Innovation #MichaelParini #AvetixGroup

Big news in #biotechnology and #celltherapy today!

🚨 Exciting updates from The BioHub! 🚨 Next week, we have an EXCLUSIVE episode featuring Spur Therapeutics. We'll dive into their rebrand from Freeline and their acquisition of SwanBio Therapeutics. Thankyou Michael Parini for joining us! 🎙️ Don't miss out! Episode drops next Wednesday. Stay tuned! #BioHubPodcast #Biotech #Pharma #Innovation #Podcast

The real story for the broader biotech market begins now as we closely watch Cargo Therapeutics' performance in the public market. This will serve as a crucial proxy for overall market sentiment towards biotech companies. How well Cargo Therapeutics navigates the post-IPO landscape can offer valuable insights into investor confidence and market trends in this sector. It's a litmus test for the resilience and appeal of the biotech industry in the eyes of public market investors. As we venture into this exciting yet uncertain terrain, I invite you to share your insights and predictions. How do you perceive the post-IPO performance of Cargo Therapeutics, and what do you think it means for the future of biotech investments? #Biotech #IPO #CargoTherapeutics #CAR_T #PublicMarkets #InvestmentTrends #HealthcareInnovation

Stop by and check out Vector Labs newest and greatest tomorrow at The Cove! Let’s talk about our new dPEG Linker platform for BioDesign of Bioconjugate Therapeutics. #vectorlabs #ADCs #dPEG #BioDesign

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/eMs9w2fF. #Biotech #oligonucleotides #EndosomalEscape

I would like to share my thoughts on Edgewise Therapeutics. I believe this company’s therapy (EDG-5506) has great potential to bring about change for patients with Becker and Duchenne Muscular Dystrophy. All of my reasoning will be provided below. #biotech #investing

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/eMs9w2fF. #Biotech #oligonucleotides #EndosomalEscape

Who is Alumis? What they are doing: The Cal-based biotech is coming out with an IPO to fund/advance several autoimmune programs, including an oral, TYK2-inh P3 program in #Psoriasis. #CompetitiveAspect: If its ESK-001 is "more selective; more potent"...could it eek ahead of Bristol Myers Squibb's #Sotyktu?? #Biotech #IPO #Pharma #Healthcare #Alumis Takeda Ventyx Biosciences #Alumis